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Abstract
The mechanisms underlying host HIV control hold much promise in the search for a func-
tional HIV cure. We investigated the host genomic signatures in elite controllers or rapid
progressors following recent infection and the correlates of immune reconstitution during
combination antiretroviral therapy. We characterized the HIV-specific longitudinal host tran-
scriptional response of peripheral blood mononuclear cells from elite controllers, rapid pro-
gressors, immune responders and non-responders using a RT-qPCR array in a cohort of
recently HIV-infected Brazilian individuals. The elite controllers expressed unique tran-
scripts early in infection that were closely associated with specialized cross-presentation
between XCR1+ DCs and antigen-specific CD8+ T cells (XCL1). The natural suppression
of HIV was also associated with the highly functional co-expression of cytokines and
chemokines (CCL2, TNF and IL-10) concomitant with the maintenance of important anti-
inflammatory and anticoagulant properties (Antithrombin III). Immune responders exhibited
exclusively upregulated mRNAs possibly related to stem cell mobilization before combina-
tion antiretroviral therapy (neutrophil elastase). Our longitudinal approach to gene expres-
sion permitted us to discover previously unrecognized determinants that contribute to
natural or antiretroviral-mediated HIV-1 immune control.
Introduction
Whereas there is a growing body of evidence recognizing the importance of host responses in
HIV infection outcomes [1], understanding how the host can control the virus may guide
novel therapeutic strategies to reverse latency and cure the infection in patients on combina-
tion antiretroviral therapy (cART), which is a major challenge. Host responses to cART can
also be heterogeneous despite achieving viral suppression and can sometimes include a lack of
proper CD4+ T cell reconstitution [2].
Although robust cytotoxic T lymphocyte (CTL) and attenuated viral fitness are associated
with spontaneous immune HIV control [3, 4], several other host genetic and immunologic
events have been described, such as an over-representation of “protective” HLA class I alleles,
including HLA-B57, HLA-B27, HLA-B13 and HLA-B58:01 [5, 6] and a higher production
of granzyme, perforin and granulysins by HIV-1-specific CD8+ T cells [7–9].
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There is still a large discrepancy between the life expectancy of the general population and
the life expectancy of an HIV-infected individual, who can experience different degrees of
‘damage-response’ framework [10] related to the long-term persistence of HIV, even with
cART [11]. Most critical are the individuals whose CD4+ T cell recovery remains impaired
despite virological suppression, which has been closely connected with several risk factors (e.g.,
increased immune activation and poor bone marrow function [12, 13]) and with an increased
risk of adverse outcomes, including serious non-AIDS events [13, 14].
To address the mechanisms underlying host HIV control and immune reconstitution dur-
ing effective cART, we focused on identifying a common host transcriptional response to HIV
infection in a cohort of recently HIV-infected Brazilian individuals. We hypothesized that a
longitudinal dissection of the gene expression that is unique to elite controllers during the ear-
liest stages of infection as well as the gene expression of individuals treated with cART might
help us better understand the host factors that contribute to the immune control of HIV-1.
Materials and methods
Study subjects
Peripheral blood mononuclear cells (PBMCs) were obtained from 20 HIV-infected individuals
enrolled in the recent HIV infection cohort in the city of Sao Paulo, Brazil [15, 16] and from 5
healthy HIV non-infected individuals. The HIV-infected individuals met the criteria to repre-
sent four outcomes, with five subjects per group: elite controllers, rapid progressors, immune
responders and immune non-responders. All subjects provided written informed consent to
participate in this study under protocols approved by the Federal University of Sao Paulo
Human Research Ethics Committee (1586/11_ID), and Ethics committee approve this consent
procedure. Written informed consents are kept in a safe cabinet at the University of Sao Paulo,
Sao Paulo, Brazil, under the guard of Professor Esper Kallas, the Principal Investigator of this
cohort of patients.
Recent infection determination. Recent infection was defined as a nonreactive detuned
HIV-1 antibody test consistent with infection for less than six months at the time of screening,
or documented seroconversion (i.e., a documented negative HIV-1 enzyme immunoassay
[EIA] or a negative or indeterminate Western blot within six months before the study). A Vir-
onostika HIV-1 Microelisa System (BioMerieux, Raleigh, NC, USA) EIA was performed as a
recent infection determination assay, with a recent infection probably acquired in the last 170
days (95% confidence interval: 145–200 days) defined as a standardized optical density mea-
surement1.0. All recently HIV-infected individuals had fully seroconverted during follow-
up after recruitment.
cART-naïve recent HIV-infected subjects. Due to the variability of definitions and fol-
low-up times in the elite controller and rapid progressor cohorts, a distinct pace of disease pro-
gression was determined based on virological and immunological criteria. Five cART-naïve
recent HIV-infected individuals defined as elite controllers and five defined as rapid progres-
sors were assessed based on the opposite slopes of their CD4+ T cell counts and viral loads over
24 months, which were retrospectively analyzed every 3 months immediately after enrollment
(Fig 1a–1d).
HIV positive elite controllers were selected based on having consecutive viral loads < 40
copies/mL after confirmed recent infection over 24 months, varying from 21 to 34 months of
undetectable viral loads (median of 29 months and mean of 28 months), with a median of 10
and a mean of 9 undetectable viral loads/subject, in the absence of viral blips. Initial bursts of
viremia of 3,800 copies/mL and 136,079 copies/mL were recorded in two elite controllers dur-
ing the early stage of infection (Fig 1a). To examine changes in the CD4+ T cell count over
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time, a linear regression analysis was generated and the highest values for slope (β, coefficient)
over 24 months following recent infection were selected. A negative slope was recorded in one
subject—that is, the count declined—because all CD4+ T cell counts were above 500 cells/mm3
over the 24 months (Fig 1b). Rapid progressors were selected based on linear regression analy-
sis of their viral loads and CD4+ T cell counts during the course of infection. Individuals with
the highest viral loads and the lowest CD4+ T cell counts over 24 months following recent HIV
infection were selected (Fig 1c and 1d). The mean and median time for rapid progressors to
evolve to a CD4+ T cell counts to a level below 350 cells/mm3 was 27 and 27 months respec-
tively. First mean and median viral loads for rapid progressors during the recent infection
period was 3.4 log and 2.9 log respectively, and mean and median viral loads after 1 year of fol-
low up (basal viral loads) was 4.2 log and 4.2 log respectively. All rapid progressors were antire-
troviral treated upon CD4+ T cell counts decreased to a level below 350 cells/mm3, but samples
were analyzed here during the antiretroviral naïve period for this group of individuals.
cART-suppressed chronic HIV-infected subjects. Due to the heterogeneity in host
responses to cART despite achieving complete suppression of the viral load, CD4+ T cell
reconstitution was evaluated in two groups of cART-suppressed chronic HIV-infected
Fig 1. Linear regression graphs of viral loads and CD4+ T cell counts over 24 months. Elite controllers (panels a and b) and rapid
progressors (panels c and d). Each dot represents data from a single recently HIV-infected individual analyzed every 3 months immediately
after cohort enrollment.
https://doi.org/10.1371/journal.pone.0169868.g001
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subjects. One of the groups was comprised of five immunological responders who presented
consecutive viral loads of< 400 copies/mL in the absence of blips during the first 12 months
of HIV suppressive cART. To examine CD4+ T cells count changes in relation to the evolution
of the infection, a linear regression model was generated and the individuals with the highest β
coefficients over 12 months following cART suppression were selected (Table 1). The other
group was comprised of five immunological non-responders selected according to previous
definitions [2], who presented consecutive viral loads of< 400 copies/mL in the absence of
blips during the first 12 months of suppressive cART and an increase in the CD4+ T cell counts
of< 30% during the first 12 months of HIV suppressive cART. An increase in the CD4+ T cell
counts of> 30% was observed in one subject who failed to acquire an absolute CD4+ T cell
count< 200 cells/mm3 during the first 12 months of viral suppression in the immunological
non-responders’ group (Table 1). cART-suppressed chronic HIV-infected subjects were
homogeneously treated with a regimen comprised of an association of fixed dose combination
of zidovudine and 3TC administered BID, and a QD dose of Efavirenz, according to the local
Brazilian guidelines at that time.
HLA class I typing, HIV subtype assignment and co-receptor tropism use
The subjects were typed for major histocompatibility complex (MHC) class I antigen expres-
sion with intermediate resolution using sequence-specific primer PCR kits (Pel-Freez SSP Uni-
Tray; Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. HIV subtype
assignment and co-receptor tropism prediction according to the gp120 V3 region DNA
sequencing were performed as previously described. [16]
Gene expression profiling and data analysis
To investigate how gene expression patterns changed over time, PBMCs were assayed from
each subject across two time points of infection. For the cART-naïve recent HIV-infected
group, time point 1 was the earliest available sample during recent HIV infection and time
point 2 was 12 months after the first time point. For the cART-suppressed chronic HIV-
infected group, time point 1 was the first available sample before treatment and time point 2
was approximately 12 months after the initiation of cART. All cART was initiated immediately
after the CD4+ T cell counts decreased to a level below 350 cells/mm3. The relative composi-
tion of CD4+ T cells, CD8+ T cells and monocytes of the bulk PBMC population analyzed have
not been analyzed.
Total RNA was isolated from (5–10) x 106 PBMCs using the RNeasy Mini Kit (cat. no.
74104; Qiagen) with on-column DNase treatment (RNase-Free DNase Set, Qiagen [cat. no.
Table 1. Characteristics of cART suppressed chronic HIV-infected patients.
Immune responders Immune non-responders
Patient ID 1046 1087 1117 2028 2033 1050 1097 2016 2020 2042
VL, before cART (copies/mL) 222000 2730 183000 506000 40500 11500 106000 62900 9330 12100
VL, 12 months after cART (copies/mL) <400 <400 <400 <400 <400 <400 <400 <400 <400 <400
CD4, before cART (cells/mm3) 268 255 261 227 235 240 83 375 143 255
CD4, 12 months after cART (cells/mm3) 628 533 496 503 450 296 185 331 112 287
Increase in CD4 during 12 months (%) 134 109 90 122 91 23 123 -12 -22 13
VL indicates viral load. The mean time of the earliest available PBMC sample before cART used for gene expression analysis was 4 months for immune
responders and 2 months for non-responders.
https://doi.org/10.1371/journal.pone.0169868.t001
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79254]) according to the manufacturer’s instructions. The RNA purity and integrity were
assessed using a NanoDrop ND-1000 spectrophotometer and a lab-on-chip Agilent RNA 6000
Nano Kit (Bioanalyzer 2100), respectively, according to Fleige and Pfaffl (2006). One micro-
gram of RNA was reverse transcribed into cDNA using the RT2 First Strand Kit (cat. no.
330401; SABiosciences) according to the manufacturer’s instructions. Quantitative real-time
PCR was assayed using a Standard SYBR Green 96-well plate PCR Array—Human HIV Infec-
tion and Host Response (cat. no. PAHS-051A; SABiosciences) following the manufacturer’s
instructions. Controls including genomic DNA, reverse-transcription and PCR controls were
performed in replicates to test for inter-well and intra-plate consistency. The B2M (Beta-
2-microglobulin), HPRT1 (Hypoxanthine phosphoribosyltransferase 1), RPL13A (Ribosomal
protein L13a), GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) and ACTB (Actin, beta)
housekeeping genes included in the arrays enabled the normalization of the data using the
Bestkeeper algorithm [17]. The same threshold value was set across all 45 samples, and the fold
change was calculated by the relative gene expression method determined using the equation
2-ΔΔCT, as previously described in the literature [18]. The results were considered statistically
significant if p 0.05 as determined by Student’s t-test, as implemented in the SABiosciences
Data Analysis package: (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Dif-
ferentially expressed genes were defined as those with at least a 2-fold change in mRNA in the
HIV-infected compared with the uninfected controls, with p 0.05. All raw data, programs
(in the R language) to process that data, figures and tables have been deposited in a publicly
available repository: https://github.com/jameshunterbr/HostTransNetwork. They are available
without restriction for consultation and use.
Results
HLA class I typing
As seen in Table 2, HLA B57 was detected in 3 out of the 5 elite controllers and was not
detected in the other groups (Fisher’s exact test, p< 0.005). Differences in the gene expression
among the elite controllers that had HLA B57 compared to those without HLA B57 included
a significant threefold upregulation of chemokine (C-C Motif) receptor 4 (CCR4) (p = 0.03)
and a threefold upregulation of complement component receptor 2 (CR2) (p = 0.01); the for-
mer is selectively expressed on the majority of Th2 cells in adult peripheral blood [19], and the
latter has been shown to play a key role in the humoral immune response [20]. There was also
a 1.8-fold upregulation of ELA2, which is involved in the egress of progenitor cells from the
bone marrow [21].
Distinctive gene expression patterns characterize cART-naïve and
cART-suppressed groups over the course of HIV infection
Based on the extensive examination of the published literature, all statistically significant fold
changes (p 0.05) were grouped into functionally similar categories, as shown in Table 3.
Immune non-responders were strikingly distinguishable from uninfected subjects, with the
highest percentage of altered transcripts (30%) after 12 months of suppressive cART. As is
depicted in Table 3, the cART-naïve and cART-suppressed groups differed over the course of
HIV infection compared with uninfected controls both quantitatively (the percentage of genes
differentially expressed) and qualitatively (functional similarities of the genes differentially
expressed). Globally, with the exception of the downregulation of CD4, CCR4 and RBL2, most
of the altered transcripts increased in expression.
Altered transcripts and HIV infection
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Enhanced mRNA expression of a unique set of chemokines and
cytokines influences HIV control during early infection
To determine the genomic contributors to the host’s capacity to control HIV replication dur-
ing early infection, we identified differentially expressed genes with a minimum 2-fold change
in mRNA in the elite controllers compared to the rapid progressors. The upregulated tran-
scripts restricted to elite controllers early in infection included genes involved in enhanced
dendritic cell cross-presentation to antigen-specific CD8+ T cells, such as XCL1/lymphotactin
(mean fold change of 4.8; p = 0.037 for elite controllers), combined with those involved in
inhibiting HIV-1 entry into mononuclear cells, such as CCL2/monocyte chemoattractant pro-
tein-1 (6.9; p = 0.03) and TNF/tumor necrosis factor-alpha (5.1; p = 0.005) and those associated
with an anti-inflammatory environment, such as IL10/interleukin-10 (3.6; p = 0.02). The genes
with greatest differences expression between Elite Controllers and Rapid Progressors during
recent infection are depicted on Fig 2a.
Elite controllers have distinct increases in the transcription factor c-Fos
and monocyte chemoattractant protein-2 (CCL8) upon 12 months of
follow-up
After 12 months of follow-up, the upregulated mRNAs in elite controllers included genes
involved in (i) R5 virus suppression (mean fold change of 2.98 and p = 0.03 for CCL8) and (ii)
the suppression of pro-inflammatory cytokine production (mean fold change of 3.8 and
Table 2. HLA class I typing according to distinct phenotypes of the response to HIV-1 infection.
Patient ID HLAB* Protective HLA
(B*57, B*27, B*13 and B*58:01)
HIV Subtype
Elite controllers 1010 B*39,B*57 Yes ND
1034 B*15, B*57 Yes ND
1073 B*35, B*57 Yes ND
1122 B*51,- No B
1168 B*35,B*40 No F
Rapid progressors 1120 B*15,B*44 No B
1141 B*45,B*52 No F
2041 B*35,B*50 No B
2044 B
2046 B*15,B*35 No B
Immune responders 1046 B*15, B*39 No B
1087 B*08,B*52 No ND
1117 B*08,B*41 No F
2028 B*35,B*45 No B
2033 B*07,B*58 Yes B
Immune non-responders 1050 B*15, B*27 Yes B
1097 B*44,B*58 Yes B
2016 B*35,B*44 No C
2020 B*07,B*44 No B
2042 B*15,B*39 No B
Protective profiles are indicated, with HLA B*57 being more prevalent among elite controllers (Fisher’s exact test, p < 0.005). HIV-1 subtype is also
indicated, according to the C2-V3-C3 region profile of the gp120 env gene. [16] (ND: not done due to the failure of PCR amplification).
https://doi.org/10.1371/journal.pone.0169868.t002
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Table 3. Mean fold changes in mRNA from HIV-infected individuals compared with uninfected controls.
cART-naïve cART-suppressed
Gene functional classification Elite controllers Rapid progressors Immune responders Immune non-responders
Recent
Infection
12 months
after
infection
Recent
Infection
12 months
after
infection
Before
cART
12 months
after cART
Before
cART
12 months
after cART
Apoptosis CASP3 2.0 CASP3 2.0 CASP3 1.7 CASP3 1.9
CASP8 2.1 CASP8 2.4
TRAIL 2.4 TRAIL 1.6
TNFR2 2.4 TNFR2 2.4 TNFR2 2.3
ASK1 1.6 ASK1 1.7 ASK1 1.5
Acute Response SERPINA1
1.8
SERPINA1
1.6
SERPINA1
1.7
ATIII 3.4 ATIII 2.3
ELA2 3.2
SLPI 2.8
MBL2 1.9 MBL2 2.0
Chemokine Receptors CCL2 6.9 CCL2 27.0
CX3CL1 1.8 CX3CL1 2.0
XCL1 4.8
CCL8 3.0 CCL8 5.4 CCL8 7.5
CCR4*
-1.5
CCR4* -1.9 CCR4* -1.6
CXCL12 2.2 CXCL12
2.0
CXCL12 3.8 CXCL12 2.4
CDs CD209 2.5
CD4* -1.6 CD4* -1.9
CD44 1.5
Cytokines TNF 5.1 TNF 3.1
IL12B 2.2
IL1B 12.7
IL10 3.6 IL10 15.2 IL10 11.3
TGFB1 1.7
Virus Budding TSG101 2.1 TSG101
1.9
TSG101 1.9 TSG101 1.7 TSG101
1.8
TSG101
1.6
TSG101 2.3
Innate Immune Response IFNA1 2.1 IFNA1 2.2
IFNG 3.4
Modulation and Differentiation STAT1 2.4 STAT1 1.9 STAT1 3.2 STAT1 3.0 STAT1 2.1 STAT1 3.1
STAT3 1.3 STAT3 1.3 STAT3 1.3
Cell Activation. Transcription and Proliferation
Proliferation Inhibitors CDKN1A
2.6
CDKN1A 2.7 CDKN1A 3.7 CDKN1A 4.9
RBL2* -1.7 RBL2* -2.0 RBL2* -2.0
Transcriptional Activation and
Elongation
CDK7 1.7 CDK7 1.7 CDK7 1.6 CDK7 1.5 CDK7 1.7
CDK9 1.5 CDK9 1.6
CCNT1 1.6 CCNT1 1.6
Transcriptional Coativators EP300 1.6
CEBPB 2.0 CEBPB
2.6
CEBPB 3.3
(Continued )
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Table 3. (Continued)
cART-naïve cART-suppressed
Gene functional classification Elite controllers Rapid progressors Immune responders Immune non-responders
Recent
Infection
12 months
after
infection
Recent
Infection
12 months
after
infection
Before
cART
12 months
after cART
Before
cART
12 months
after cART
AP-1 and NF-κB Transcriptional
Activation
FOS 3.8 FOS 7.2 FOS 8.1 FOS 8.3
LTBR 1.4 LTBR 1.6 LTBR 1.5 LTBR 1.5 LTBR 2.2
The table shows only genes with statistically significance at the 0.05 level between the two groups. The groups and different time points studied are
depicted as columns. All genes are expressed at higher levels than the control, and the fold change is depicted to the right of each gene. The more
differentially expressed genes are highlighted in bold.
*Asterisks indicate downregulated genes.
https://doi.org/10.1371/journal.pone.0169868.t003
Fig 2. Differences in gene expression between cART-naïve and cART-suppressed groups (p<0.05). (a) Elite Controllers and Rapid
Progressors during recent HIV-1 infection. (b) Elite Controllers and Rapid Progressors after 12 months of cohort recruitment. (c)
Immunological Responders and Immunological non-responders immediately before antiretroviral treatment initiation. (d) Immunological
Responders and Immunological non-responders after 12 months of antiretroviral treatment initiation).
https://doi.org/10.1371/journal.pone.0169868.g002
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p = 0.04 for FOS). The genes with greatest differences expression between Elite Controllers
and Rapid Progressors after 12 months of follow up are depicted on Fig 2b.
Antithrombin III (ATIII) expression is associated with durable virus
control over time
Throughout the infection period, defense mechanisms may have contributed to spontaneous
control of HIV-1 in elite controllers, including the potent anticoagulant activity exerted by
high antithrombin III (ATIII) expression (mean fold change of 3.4; p = 0.039 for elite control-
lers in an early stage of infection and 2.3; p = 0.049 in the chronic stage).
Acute phase proteins and TNF-αmay predict immune reconstitution
before cART
To predict the genomic determinants of the host’s capacity for successful CD4+ T cell recovery,
we identified uniquely altered genes in the immune responders compared to the non-respond-
ers before cART. The upregulated transcripts restricted to immune responders before treat-
ment included genes involved in the egress of progenitor cells from the bone marrow, as
suggested by an increase in ELA2 (mean fold change of 3.16; p = 0.02), combined with their
natural regulators, represented by SLPI (mean fold change of 2.82; p = 0.01). High TNF expres-
sion may indicate the inhibition of HIV-1 entry into mononuclear cells. The genes with great-
est differences expression between immunological responders and INR immediately before
antiretroviral treatment ignition and after 12 month of antiretroviral treatment are depicted
on Fig 2c and 2d.
Discussion
The ultimate outcomes of HIV-1 infection depend on the initial host-viral interactions that
occur early during infection [22, 23]. We therefore chose a cohort of recently HIV-infected
individuals in the city of Sao Paulo, Brazil to help delineate the temporal genomic factors that
contribute to spontaneous or artificial HIV-1 immune control. We used data from these indi-
viduals to evaluate common and specific gene expression patterns in the antiretroviral naïve
individuals experiencing a distinct pace of HIV disease progression and individuals experienc-
ing discordant CD4+ T cell recovery after cART. This cohort was ideal for these studies
because PBMC samples were available following recent infection and because the cART-sup-
pressed chronic HIV-infected subjects were also evaluated from the same well-characterized
population under equal conditions.
We are not aware of any data in the literature on the capacity of elite controllers during
early infection to express higher levels of XCL1. Here, we provide evidence that PBMCs from
elite controllers during early infection produce higher mRNA levels of XCL1 than PBMCs
from uninfected subjects. XCL1 is primarily produced by activated CD8+ T cells and NK cells
[24] and recruits T lymphocytes and dendritic cells by binding to and activating its specific cel-
lular receptor, XCR1 [25, 26]. XCL1 was recently reported to inhibit HIV-1 at an early step of
the viral replication cycle via the blockade of viral attachment and entry into host cells [27].
Our results seem to be consistent with a recent observation that described substantial increases
in the abundance of mRNAs encoding lymphotactin (XCL1); the antiviral cytokines macro-
phage inflammatory proteins MIP-1α, MIP-1αP (CCL3L1), and MIP-1β; granulocyte-macro-
phage colony-stimulating factor (GM-CSF); tumor necrosis factor receptor superfamily
member 9 (TNFRSF9); and gamma interferon (IFN-γ) in Gag p24- and Nef-specific CD8+ T
cells from HIV-1-infected virus controllers (VCs) (less than 5,000 HIV-1 RNA copies/mL and
Altered transcripts and HIV infection
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CD4+ lymphocyte counts of higher than 400 cells/mm3) [28]. The recent demonstration that
there is an association between CD8+ T cells and primary human CD141+ DCs should also be
considered. When dendritic cells (DCs) are not directly infected, the debris of cells that were
infected and have subsequently undergone apoptosis is taken up and cross-presented by spe-
cialized DCs to CD8+ T cells. In humans, primary CD141+ DCs are the only DC population in
the blood that expresses the chemokine receptor XCR1 and responds to the specific ligand
XCL1 with Ca2+ mobilization and potent chemotaxis. CD141+ DCs excel in the cross-presen-
tation of soluble or cell-associated antigens to CD8+ T cells when directly compared with
CD1c+ DCs, CD16+ DCs, and plasmacytoid DCs (pDCs) [29]. In this regard, we suggest that
our observation of upregulated XCL1 only in elite controllers during early infection might
indicate communication between cross-presenting XCR1+DCs and antigen-specific CD8+ T
cells that should be investigated in future studies. We recognize that the assessment of XCL1 in
CD8+ cells would be strongly required to validate the above results and confirm our hypothe-
sis, but unfortunately, we do not have further access to biologic material of those patients.
In addition, our transcriptional profiling identified a functional difference between well-
documented cytokines and chemokines between elite controllers and rapid progressors during
early infection; there was a significant co-expression of MCP1, TNF and IL10 only in elite
controllers. These findings correspond to studies that show that the functionality of the HIV-
specific T-cell response is a clinical correlate of protection from disease progression [30]. Inter-
estingly, in addition to a higher prevalence of HLA B57 among elite controllers, which has
already been described as a protective phenotype against HIV disease progression [5, 6],
CCR4,CR2 and ELA2were also hyperexpressed among HLA B57-expressing elite controllers
compared to non-HLA B57 individuals. These data suggest different mechanisms of HIV
control among different human hosts.
Importantly, there is also a great need to reduce HIV-induced inflammation and its chronic
consequences, including cardiovascular diseases and HIV-related dementia. Here, we present
evidence that our cART-naïve patients seem to have achieved one year of control over HIV
replication with no decay of CD4+ T cells thanks to an exceptional increase in the expression
of the chemokine MCP-2 and the transcription factor c-Fos. This is in agreement with previ-
ous results showing that MCP-2 is a ligand for CCR5 on CD4+ lymphocytes and that it can
specifically block R5 HIV-1 [31]. Although data focusing on c-Fos in the pathogenesis of
HIV infection are scarce, our current results may be related to the reported capacity of this
component of AP-1 to mediate an immunosuppressive effect, acting as an anti-inflammatory
transcription factor in vivo [32–34]. However, the direct impact of c-Fos on the proper mainte-
nance of such immune regulation deserves further exploration. Concurrently and as a novel
finding, we found that the serpin antithrombin III was uniquely upregulated in elite control-
lers throughout the infection period, which may have had beneficial effects on the limitation
of coagulopathic damage [35]. Antithrombin III exerts an anti-inflammatory activity that is
mediated in part by the reduction of NF-kappa B activity [36] and, ultimately, the inhibition of
HIV-1 replication [37, 38]. Together, these findings indicate that elite controllers are highly
equipped to effectively restrain the virus and modulate immune activation starting in the early
stages of infection.
We also examined the variability of CD4+ T cell recovery to more fully understand the
genomic determinants of immunologic efficacy. Remarkably, as a result of these investigations,
we found a high level of neutrophil elastase (ELA2), which is not expressed by neutrophils, but
by their bone marrow precursor cells [21]. As a novel finding as well, we observed ELA2 tran-
script levels in PBMCs from immunological responders before cART, which was unexpected
and suggests that mechanisms underlying the mobilization of hematopoietic progenitor cells
are possibly involved. It has previously been proposed that increased intramedullary elastase
Altered transcripts and HIV infection
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cleaves stromal cell vascular cellular adhesion molecule-1 (VCAM-1), reducing cellular adhe-
siveness and mobilizing marrow cells in the circulatory system [39]. Although our results may
eventually predict immune reconstitution following cART, they require further investigation.
It is interesting to note that one of the natural regulators of neutrophil elastase, the secretory
leukocyte protease inhibitor (SLPI) [40, 41], was also found to be consistently upregulated
only in the same immune responders before cART, confirming its well-documented dose-
dependent reciprocal feedback regulation [42–44]. In addition to its antiprotease activity, SLPI
has been shown to inhibit NF-kB activation in monocytes [45], exerting anti-inflammatory
effects, and to inhibit the ELA2-dependent conversion of proepithelin to epithelin, thereby
stimulating wound healing by promoting epithelial cell growth [46]. Furthermore, in the con-
text of susceptibility to HIV infection, high expression of SLPI has been frequently shown to
be a protector factor [47]. Taken together, these key effectors of the innate immune system
may effectively predict immune reconstitution before cART.
This study has some limitations. First, we investigated a relatively small sample size, and
our results need to be confirmed in larger populations of HIV-infected elite controllers, rapid
progressors and cART-suppressed individuals. Therefore, the results presented here should be
considered preliminary. Second, this study was performed using RNA isolation from bulk
PBMCs, and as such, it cannot determine which cells are demonstrating altered gene expres-
sion. Therefore, further functional and diagnostic approaches, such as the identification and
sorting of elite controller and immunological non-responder cell subsets, ex-vivo infection
assays in cell culture or siRNA-mediated gene knockdown, will be important in advancing the
findings presented here in future studies. Furthermore, although we applied a systematic com-
parison across all studied groups, we intentionally chose to explore and discuss only the unique
differentially expressed genes (at least a 2-fold change, with p 0.05) in elite controllers and
immune responders due to space limitations. However, this study was able to focus on a non-
specific predefined pathway, enabling us to discover previously unrecognized correlates of
immune protection and providing insights in the search for a functional cure among HIV-
infected individuals.
Conclusions
Differentially expressed genes drive phenotype variation, and this study solidifies the notion
that elite controllers in the early stages of HIV infection have unique genetically programmed
immune responses to control initial HIV spread while maintaining anti-inflammatory signal-
ing in peripheral mononuclear cells. We have shown that altered transcripts vary across cART-
naïve and cART-suppressed groups over time in the course of HIV infection compared with
uninfected controls. The management of HIV patients experiencing distinct immune reconsti-
tution during effective cART may be improved by understanding more about the specific
interplay of key effectors of the innate immune system associated with stem cell mobilization.
Once identified, the integrative mechanisms underlying host HIV control should allow us to
understand the nature of the immunologic efficacy associated with these rare infected individ-
uals and to eventually exploit these mechanisms to promote a functional HIV cure with strate-
gies including the promotion of antithrombin III coagulation activity or the upregulation of c-
Fos-related pro-inflammatory activity.
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